R&D News | pharmaphorum

News

Takeda proposes selling Shire’s IBD treatment after merger

Takeda has proposed selling off a Shire treatment for inflammatory bowel disease when the companies merge next year, to avoid an overlap with its own drug.

News

Psilocybin is a naturally occurring psychedelic prodrug compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.

Magic mushroom drug could be depression breakthrough, says F...

The liberty cap mushroom, notoriously used illegally as a psychoactive drug, could be the inspiration for a new therapy for depression according to the US drug regulator.

News

Lundbeck craters as resistant schizophrenia drug fails phase...

Danish drugmaker Lundbeck saw more than a quarter of the value wiped off its shares yesterday after its top pipeline prospect, a drug for schizophrenia, missed the mark in a phase III trial.

News

J&J builds case for HIV vaccine ahead of pivotal trial reado...

Johnson & Johnson has moved a step closer to the goal of developing a vaccine that can help prevent HIV infection, thanks to positive data from a phase 1/2a trial.

News

Sanofi/Regeneron's Dupixent could be first biologic approved...

Trials of Sanofi and Regeneron’s drug Dupixent (dupilumab) have shown positive results for treating patients suffering from chronic rhinosinusitis with nasal polyps, teeing up a potential n

News

Merck KGaA's BTK drug reduces lesions in relapsing MS patien...

Germany’s Merck KGaA has said it is “encouraged” by mid-stage trial results showing that its Bruton’s kinase (BTK) class drug evobrutinib reduced occurrence of central nervous system lesion

Takeda proposes selling Shire’s IBD treatment after merger

Magic mushroom drug could be depression breakthrough, says F...

Lundbeck craters as resistant schizophrenia drug fails phase...

J&J builds case for HIV vaccine ahead of pivotal trial reado...

Sanofi/Regeneron's Dupixent could be first biologic approved...

Merck KGaA's BTK drug reduces lesions in relapsing MS patien...

Bavarian Nordic has found its new CEO

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks